Skip to main content

Table 4 Multivariate analysis of TRPM7 methylation with clinicopathological characteristics in Luminal A and B breast cancers

From: Promoter methylation of transient receptor potential melastatin-related 7 (TRPM7) predicts a better prognosis in patients with Luminal A breast cancers

Characteristics

Luminal A

Luminal B

ORa (95% CI)

P

ORa (95% CI)

P

Ageb

0.91 (0.58–1.43)

0.68

1.57 (0.95–2.59)

0.08

LNMc

0.03 (0.001–0.59)

0.02

0.55 (0.07–4.63)

0.59

Endocrine therapy

0.60 (0.19–1.83)

0.37

8.49 (2.10–34.29)

0.003

Radiotherapy

2.62 (0.22–31.59)

0.45

0.27 (0.03–2.20)

0.22

Chemotherapy

0.65 (0.18–2.38)

0.51

2.65 (0.40–17.55)

0.31

Survival statusd

0.26 (0.05–1.36)

0.11

0.56 (0.11–2.76)

0.48

  1. aOR: odds ratio with 95% confidence interval; bAge (per 10 years); cLymph node metastasis; dSurvival status (alive vs. dead)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us